Comparing breast cancer risk assessment models

Journal of the National Cancer Institute

Volumn 102, Issue 10, 2010, Pages 665-668

  Gail, Mitchell H ^a   Mai, Phuong L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

AUTOSOMAL DOMINANT INHERITANCE; BREAST CANCER; CALIBRATION; CANCER DIAGNOSIS; CANCER RISK; CHEMOPROPHYLAXIS; COWDEN SYNDROME; EDITORIAL; FAMILIAL CANCER; FAMILY HISTORY; GENE EXPRESSION REGULATION; GENE MUTATION; GENOTYPE; HIGH RISK POPULATION; HUMAN; LUNG EMBOLISM; OVARY CANCER; PRIORITY JOURNAL; RISK ASSESSMENT; STROKE; TUMOR BIOPSY;

BREAST NEOPLASMS; DECISION SUPPORT TECHNIQUES; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GERM-LINE MUTATION; GREAT BRITAIN; HUMANS; MAMMOGRAPHY; MASS SCREENING; MODELS, STATISTICAL; POPULATION SURVEILLANCE; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS; UNITED STATES;

EID: 77952919497     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djq141     Document Type: Editorial

References (30)

1. Amir E, Freedman OC, Seruga B, Evans DG. Assessing women at high risk of breast cancer: a review of risk assessment models. J Natl Cancer Inst. 2010;102(10):680-691.
2. Frank TS, Deffenbaugh AM, Reid JE, et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol. 2002;20(6):1480-1490.
3. Evans DGR, Eccles DM, Rahman N, et al. A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO. J Med Genet. 2004;41(6):474-480.
4. Berry DA, Parmigiani G, Sanchez J, Schildkraut J, Winer E. Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. J Natl Cancer Inst. 1997;89(3):227-238.
5. Chen SN, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 pene-trance. J Clin Oncol. 2007;25(11):1329-1333.
6. Antoniou AC, Cunningham AP, Peto J, et al. The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer. 2008;98(8):1457-1466.
7. Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med. 2004;23(7):1111- 1130.
8. Antoniou AC, Hardy R, Walker L, et al. Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics. J Med Genet. 2008;45(7):425-431.
9. Gail MH, Costantino JP, Bryant J, et al. Weighing the risks and benefts of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst. 1999;91(21):1829-1846.
10. Costantino JP, Gail MH, Pee D, et al. Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst. 1999;91(18):1541-1548.
11. Rockhill B, Spiegelman D, Byrne C, Hunter DJ, Colditz GA. Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst. 2001;93(5):358-366.
12. Chlebowski RT, Anderson GL, Lane DS, et al. Predicting risk of breast cancer in postmenopausal women by hormone receptor status. J Natl Cancer Inst. 2007;99(22):1695-1705.
13. Amir E, Evans DG, Shenton A, et al. Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme. J Med Genet. 2003;40(11):807-814.
14. Bondy ML, Lustbader ED, Halabi S, Ross E, Vogel VG. Validation of a breast-cancer risk assessment model in women with a positive family history. J Natl Cancer Inst. 1994;86(8):620-625.
15. Claus EB, Risch N, Thompson WD. Autosomal-dominant inheritance of early-onset breast-cancer\implications for risk prediction. Cancer. 1994;73(3):643-651.
16. Brinton LA, Sherman ME, Carreon JD, Anderson WF. Recent trends in breast cancer among younger women in the United States. J Natl Cancer Inst. 2008;100(22):1643-1648.
17. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90(18): 1371-1388.
18. Pankratz VS, Hartmann LC, Degnim AC, et al. Assessment of the accuracy of the Gail model in women with atypical hyperplasia. J Clin Oncol. 2008;26(33):5374-5379.
19. Baker SG, Kramer BS. Peirce, Youden, and receiver operating characteristic curves. Am Stat. 2007;61(4):343-346.
20. Gail MH, Pfeiffer RM. On criteria for evaluating models of absolute risk. Biostatistics. 2005;6(2):227-239.
21. Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making. 2006;26(6):565-574.
22. Euhus DM, Leitch AM, Huth JF, Peters GN. Limitations of the Gail model in the specialized breast cancer risk assessment clinic. Breast J. 2002;8(1):23-27.
23. Travis LB, Hill D, Dores GM, et al. Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst. 2005;97(19):1428-1437.
24. Bodian CA, Perzin KH, Lattes R. Lobular neoplasia\long term risk of breast cancer and relation to other factors. Cancer. 1996;78(5):1024-1034.
25. Schonfeld SJ, Pee D, Greenlee RT, et al. Effect of changing breast cancer incidence rates on the calibration of the Gail model [published online ahead of print April 5, 2010]. J Clin Oncol.
26. Gail MH. Applying the Lorenz curve to disease risk to optimize health benefts under cost constraints. Stat Interface. 2009;2(2):117-121.
27. Gail MH. Discriminatory accuracy from single-nucleotide polymorphisms in models to predict breast cancer risk. J Natl Cancer Inst. 2008;100(14): 1037-1041.
28. Gail MH. Value of adding single-nucleotide polymorphism genotypes to a breast cancer risk model. J Natl Cancer Inst. 2009;101(13):959-963.
29. Pharoah PDP, Antoniou AC, Easton DF, Ponder BAJ. Polygenes, risk prediction, and targeted prevention of breast cancer. N Engl J Med. 2008;358(26):2796-2803.
30. Wacholder S, Hartge P, Prentice R, et al. Adding common genetic variants to breast cancer risk models. N Engl J Med. 2010;362(11):986-993.